ECO Animal Health Group plc (LON:EAH) Soars 28% But It’s A Story Of Risk Vs Reward

Those holding ECO Animal Health Group plc (LON:EAH) shares would be relieved that the share price has rebounded 28% in the last thirty days, but it needs to keep going to repair the recent damage it has caused to investor portfolios. Not all shareholders will be feeling jubilant, since the share price is still down a very disappointing 11% in the last twelve months.

Although its price has surged higher, ECO Animal Health Group may still look like a strong buying opportunity at present with its price-to-sales (or “P/S”) ratio of 0.8x, considering almost half of all companies in the Pharmaceuticals industry in the United Kingdom have P/S ratios greater than 3.7x and even P/S higher than 24x aren’t out of the ordinary. However, the P/S might be quite low for a reason and it requires further investigation to determine if it’s justified.

View our latest analysis for ECO Animal Health Group

How ECO Animal Health Group Has Been Performing

ECO Animal Health Group certainly has been doing a good job lately as it’s been growing revenue more than most other companies. Perhaps the market is expecting future revenue performance to dive, which has kept the P/S suppressed. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price.

Want the full picture on analyst estimates for the company? Then our free report on ECO Animal Health Group will help you uncover what’s on the horizon.

How Is ECO Animal Health Group’s Revenue Growth Trending?

ECO Animal Health Group’s P/S ratio would be typical for a company that’s expected to deliver very poor growth or even falling revenue, and importantly, perform much worse than the industry.

Retrospectively, the last year delivered a decent 13% gain to the company’s revenues. However, due to its less than impressive performance prior to this period, revenue growth is practically non-existent over the last three years overall. Accordingly, shareholders probably wouldn’t have been overly satisfied with the unstable medium-term growth rates.

Looking ahead now, revenue is anticipated to climb by 5.7% each year during the coming three years according to the four analysts following the company. Meanwhile, the rest of the industry is forecast to expand by 6.6% per annum, which is not materially different.

With this in consideration, we find it intriguing that ECO Animal Health Group’s P/S is lagging behind its industry peers. Apparently some shareholders are doubtful of the forecasts and have been accepting lower selling prices.

The Final Word

Even after such a strong price move, ECO Animal Health Group’s P/S still trails the rest of the industry. Generally, our preference is to limit the use of the price-to-sales ratio to establishing what the market thinks about the overall health of a company.

We’ve seen that ECO Animal Health Group currently trades on a lower than expected P/S since its forecast growth is in line with the wider industry. Despite average revenue growth estimates, there could be some unobserved threats keeping the P/S low. It appears some are indeed anticipating revenue instability, because these conditions should normally provide more support to the share price.

Plus, you should also learn about this 1 warning sign we’ve spotted with ECO Animal Health Group.

If you’re unsure about the strength of ECO Animal Health Group’s business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.